Matches in SemOpenAlex for { <https://semopenalex.org/work/W2294992029> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2294992029 endingPage "230" @default.
- W2294992029 startingPage "229" @default.
- W2294992029 abstract "C infections with the hepatitis C virus (HCV) represent a major global health problem, with around 170 million patients at risk of developing life-threatening complications such as liver cirrhosis or hepatocellular carcinoma. The standard treatment of care is a combination of weekly pegylated interferon (peginterferon) alfa and daily ribavirin for 24-72 weeks, dependent on HCV genotype and the patient’s individual virological response to therapy (1, 2). Currently, there are two forms of peginterferon licensed for the treatment of hepatitis C: peginterferon alfa-2a (Pegasys, Roche) and peginterferon alfa-2b (Pegintron, Schering-Plough). Although direct pharmacodynamic comparisons of both substances have shown that they differ considerably with respect to pharmocokinetics and initial virological suppression (3), it remained largely unclear whether this is relevant for clinical endpoints, especially for achieving sustained virological response in HCV-infected patients. In fact, the largest phase-3 trials for peginterferon alfa-2a and alfa-2b initially yielded somewhat similar outcomes (4, 5), establishing a “gut feeling” among many hepatologists worldwide that both substances were very likely equally potent in clinical practice. This was strongly supported by the largest endpoint trial to directly compare these two peginterferons, the IDEAL trial. In this trial, more than 3,000 patients were randomized to receive either peginterferon alfa-2b (at two different doses, i.e. 1.0 or 1.5 μg/kg per week) or alfa-2a (at 180 μg/week), and similar sustained virological response (SVR) rates were reported for all three treatment groups (6). Two smaller recent studies reported by Rumi and Ascione this year (7, 8) challenged this conclusion by revealing a modest but significant increase in SVR for patients treated with peginterferon alfa-2a (Table 1). However, findings from single trials, especially when yielding contradictory results, are rarely definitive. It is therefore important to conduct a metaanalysis of the available high-quality studies. Prof. Alavian and colleagues present in this issue of Hepatitis Monthly a thorough, up-to-date, and extensive metaanalysis of studies comparing the efficacy of the two peginterferons in patients chronically infected by HCV (9). This meta-analysis included 3,518 patients" @default.
- W2294992029 created "2016-06-24" @default.
- W2294992029 creator A5083825910 @default.
- W2294992029 date "2010-01-01" @default.
- W2294992029 modified "2023-09-27" @default.
- W2294992029 title "LETTER TO EDITOR: WHICH IS THE IDEAL PEGINTERFERON FOR HEPATITIS C: A META-ANALYSIS OF BOTH PEGYLATED INTERFERONS IN THE TREATMENT OF HCV-INFECTED PATIENTS" @default.
- W2294992029 cites W1964471673 @default.
- W2294992029 cites W2026329262 @default.
- W2294992029 cites W2027545702 @default.
- W2294992029 cites W2075282196 @default.
- W2294992029 cites W2116998683 @default.
- W2294992029 cites W2118259710 @default.
- W2294992029 cites W2127685726 @default.
- W2294992029 cites W2141468375 @default.
- W2294992029 cites W2150875695 @default.
- W2294992029 hasPublicationYear "2010" @default.
- W2294992029 type Work @default.
- W2294992029 sameAs 2294992029 @default.
- W2294992029 citedByCount "0" @default.
- W2294992029 crossrefType "journal-article" @default.
- W2294992029 hasAuthorship W2294992029A5083825910 @default.
- W2294992029 hasConcept C126322002 @default.
- W2294992029 hasConcept C203014093 @default.
- W2294992029 hasConcept C203092338 @default.
- W2294992029 hasConcept C2522874641 @default.
- W2294992029 hasConcept C2776235749 @default.
- W2294992029 hasConcept C2776408679 @default.
- W2294992029 hasConcept C2776455275 @default.
- W2294992029 hasConcept C2776461080 @default.
- W2294992029 hasConcept C2780040827 @default.
- W2294992029 hasConcept C535046627 @default.
- W2294992029 hasConcept C61943457 @default.
- W2294992029 hasConcept C71924100 @default.
- W2294992029 hasConcept C90924648 @default.
- W2294992029 hasConceptScore W2294992029C126322002 @default.
- W2294992029 hasConceptScore W2294992029C203014093 @default.
- W2294992029 hasConceptScore W2294992029C203092338 @default.
- W2294992029 hasConceptScore W2294992029C2522874641 @default.
- W2294992029 hasConceptScore W2294992029C2776235749 @default.
- W2294992029 hasConceptScore W2294992029C2776408679 @default.
- W2294992029 hasConceptScore W2294992029C2776455275 @default.
- W2294992029 hasConceptScore W2294992029C2776461080 @default.
- W2294992029 hasConceptScore W2294992029C2780040827 @default.
- W2294992029 hasConceptScore W2294992029C535046627 @default.
- W2294992029 hasConceptScore W2294992029C61943457 @default.
- W2294992029 hasConceptScore W2294992029C71924100 @default.
- W2294992029 hasConceptScore W2294992029C90924648 @default.
- W2294992029 hasIssue "328" @default.
- W2294992029 hasLocation W22949920291 @default.
- W2294992029 hasOpenAccess W2294992029 @default.
- W2294992029 hasPrimaryLocation W22949920291 @default.
- W2294992029 hasRelatedWork W1711532966 @default.
- W2294992029 hasRelatedWork W1982524414 @default.
- W2294992029 hasRelatedWork W2002461395 @default.
- W2294992029 hasRelatedWork W2032629728 @default.
- W2294992029 hasRelatedWork W2039885146 @default.
- W2294992029 hasRelatedWork W2057271447 @default.
- W2294992029 hasRelatedWork W2093121895 @default.
- W2294992029 hasRelatedWork W2111457004 @default.
- W2294992029 hasRelatedWork W2131228788 @default.
- W2294992029 hasRelatedWork W2132503465 @default.
- W2294992029 hasRelatedWork W2135996840 @default.
- W2294992029 hasRelatedWork W2145735401 @default.
- W2294992029 hasRelatedWork W2160432577 @default.
- W2294992029 hasRelatedWork W2242497769 @default.
- W2294992029 hasRelatedWork W2266817085 @default.
- W2294992029 hasRelatedWork W2280095500 @default.
- W2294992029 hasRelatedWork W2331499216 @default.
- W2294992029 hasRelatedWork W2740983563 @default.
- W2294992029 hasRelatedWork W2783978214 @default.
- W2294992029 hasRelatedWork W89538224 @default.
- W2294992029 hasVolume "10" @default.
- W2294992029 isParatext "false" @default.
- W2294992029 isRetracted "false" @default.
- W2294992029 magId "2294992029" @default.
- W2294992029 workType "letter" @default.